Celcuity (NASDAQ:CELC) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $134.00. They now have a "buy" rating on the stock.
Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge [Yahoo! Finance]